Details
Atrial fibrillation affects up to 70% of patients with ATTR-CM—but how does it impact treatment outcomes?
Dr. Brett Sperry and I discuss new findings showing that acoramidis delivered consistent clinical benefits regardless of baseline atrial fibrillation status and was associated with fewer new or worsening AF events.
https://lnkd.in/e_ScvkH9